US 11,655,296 B2
Anti-CD47 antibody and use thereof
Dandan Liu, Jiangsu (CN); Weifeng Huang, Jiangsu (CN); Bingliang Chen, Jiangsu (CN); and Junjian Liu, Jiangsu (CN)
Assigned to INNOVENT BIOLOGICS (SUZHOU) CO., LTD., Jiangsu (CN)
Appl. No. 16/966,081
Filed by INNOVENT BIOLOGICS (SUZHOU) CO., LTD., Jiangsu (CN)
PCT Filed Mar. 26, 2019, PCT No. PCT/CN2019/079687
§ 371(c)(1), (2) Date Jul. 30, 2020,
PCT Pub. No. WO2019/184912, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 201810259545.2 (CN), filed on Mar. 27, 2018.
Prior Publication US 2020/0377593 A1, Dec. 3, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); G01N 33/57492 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. An isolated anti-CD47 monoclonal antibody or an antigen-binding fragment thereof, comprising: 3 heavy chain complementarity determining regions (CDRs) of a heavy chain variable region (HCDR1, HCDR2, HCDR3) and 3 light chain CDRs of a light chain variable region (LCDR1, LCDR2, LCDR3), wherein:
(i) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 15, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 21, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 41;
(ii) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 16, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 22, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 41;
(iii) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 23, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 31, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 41;
(iv) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 18, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42;
(v) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 25, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 33, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42;
(vi) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 19, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 26, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42;
(vii) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 16, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 27, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 34, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 40, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 43;
(viii) HCDR1 comprises the amino acid sequence v SEQ ID NO: 20, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 34, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 40, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 43;
(ix) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 16, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 29, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 35, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 38, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 44; or
(x) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 20, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 30, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 35, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 38, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 39, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 44.